Major Shift: Private Companies Now Leading Cell Therapy Research for Type 1 Diabetes

The Juvenile Diabetes Cure Alliance (JDCA) released its 14th annual State of the Cure for Type 1 Diabetes report in January 2026, marking a significant moment in how the field approaches a cure. For the first time, the report highlights a major transition: cell supply research is shifting from nonprofit and government-funded institutions to commercial companies.

This change reflects a growing belief among investors and researchers that stem cell-derived beta cells—insulin-producing cells created in the laboratory—represent a realistic path forward for treating type 1 diabetes.

Type 1 diabetes is an autoimmune condition in which the body's own immune system destroys insulin-producing beta cells in the pancreas. This leaves people dependent on insulin therapy and continuous blood sugar management for life.

For years, research into cell replacement therapy was primarily conducted and funded by nonprofits and government agencies exploring whether scientists could grow replacement beta cells. The new report shows that large and small commercial companies are now entering this space, bringing capital, resources, and business momentum to the field.

The movement of companies into cell therapy research has been driven by demonstrated success in clinical trials. Stem cell-derived beta cells have shown they can function as a viable replacement method, supporting the idea that this approach deserves serious investment and development.

According to Phil Shaw, Executive Director of JDCA, this represents a fundamental shift in cure research. 'We are witnessing a fundamental shift in cure research for type 1 diabetes that can lead to game-changing breakthroughs in the near term,' Shaw said in the report announcement.

The increased commercial activity signals that the sector is attracting meaningful capital. While cell replacement therapy remains in development, the growing private investment suggests researchers and companies believe significant progress is possible in the coming years.

The annual State of the Cure report will continue to track these developments, monitoring how both nonprofit and commercial efforts advance toward more effective treatments for type 1 diabetes.

Origin: GlobeNewswire News Room (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.